Novaliq at Ophthalmology Technology Summit 2018
June 26, 2018 – We are delighted that Novaliq was selected as one of only four companies to present in OCTANe’s LaunchPad session during the Ophthalmology Technology Summit taking place in Newport Beach, CA on June 29, 2018. Novaliq Inc‘s president, Bernhard Günther, will present between 3:15-4:15 p.m. https://www.ots2018.com/agenda/Study finds NovaTears increases tear film, lipid layer thickness.
June 5, 2018 – Gerard Garhöfer, MD, and colleagues reported in a randomized study, that NovaTears has the ability to restore the tear film over time, due to the novel mode of action – perfluorohexyloctane – preventing evaporation by stabilizing the lipid layer.
Study finds NovaTears increases tear film, lipid layer thickness
June 4, 2018 – Gerard Garhöfer, MD, and colleagues reported in a randomized study, that NovaTears has the ability to restore the tear film over time, due to the novel mode of action – perfluorohexyloctane – preventing evaporation by stabilizing the lipid layer.
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI
Heidelberg, Germany – April 24, 2018 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3).
What opportunities does the dry eye challenge hold for the ophthalmology industry?
March 19, 2018 –Christian Roesky, PhD, CEO and managing director of Novaliq GmbH, explains how the company’s water-free ophthalmic therapies can bring new treatments to ophthalmology’s most vexing conditions including dry eye. And what valuable lessons has he learned as CEO of the start-up.
Novaliq Announces First Patient Enrolled in Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Dry Eye Disease
Heidelberg, Germany – January 8, 2018 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that it has begun randomization of patients in its SEECASE Phase 2 clinical trial for the treatment of dry eye disease (DED).
Novaliq Establishes U.S. Subsidiary in Cambridge, Massachusetts to Strengthen Its Presence in the Growing U.S. Eye Care Market
Heidelberg, Germany – January 8, 2018 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the formation of its new subsidiary, Novaliq Inc., which will be located in Cambridge, Massachusetts, U.S.